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Abstract
Staphylococcus aureus is the most prevalent organism isolated from the airways of people with cystic fibrosis (CF), predomi-
nantly early in life. Yet its role in the pathology of lung disease is poorly understood. In mice, and many experiments using cell 
lines, the bacterium invades cells or interstitium, and forms abscesses. This is at odds with the limited available clinical data: 
interstitial bacteria are rare in CF biopsies and abscesses are highly unusual. Bacteria instead appear to localize in mucus 
plugs in the lumens of bronchioles. We show that, in an established ex vivo model of CF infection comprising porcine bronchiolar 
tissue and synthetic mucus, S. aureus demonstrates clinically significant characteristics including colonization of the airway 
lumen, with preferential localization as multicellular aggregates in mucus, initiation of a small colony variant phenotype and 
increased antibiotic tolerance of tissue- associated aggregates. Tissue invasion and abscesses were not observed. Our results 
may inform ongoing debates relating to clinical responses to S. aureus in people with CF.
DATA SUMMARY
The authors confirm all supporting data, code and protocols 
have been provided within the article or through supplemen-
tary data files.
INTRODUCTION
Staphylococcus aureus is currently the most prevalent path-
ogen isolated from the airways of people with cystic fibrosis 
(CF) [1]. Historically, it is has been associated predominantly 
with paediatric pulmonary infection [2], yet the most recent 
data shows that ~50 % of even the oldest patients are now 
colonized [3]. The presence of S. aureus in the respiratory 
tract varies considerably geographically and over time, and 
although prevalence appears to decrease with age [4] MRSA 
is most prevalent between 10–30 year olds [3]. Determining 
the difference between colonization and infection is both 
important and difficult. Nasal carriage of S. aureus among 
children with CF is common: Stone et al. [5] reported that 
52.4 % of the infants they studied harboured the organism. 
However, relatively high carriage rates in healthy children 
have also been recorded [6]. Further, expectorate is difficult 
to collect from infants, so samples are usually collected by 
oropharyngeal swab, but the presence of organisms in the 
upper respiratory tract is not always indicative of lower airway 
infection [7, 8].
Moreover, the association of S. aureus with progressive lung 
disease – as measured by worsening lung function and the 
development of subsequent infection by the chronic CF 
pathogen Pseudomonas aeruginosa – is unclear [9]. S. aureus 
is able to rapidly adapt to and persist in the CF lung environ-
ment [10], and worsening lung condition has been associated 
with the formation of S. aureus small colony variants (SCVs) 
[11]. SCVs are known to remain in the lung longer than WT 
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bacterial cells [12] and demonstrate increased antimicrobial 
resistance [13]. In studies of bronchoalveolar lavage (BAL) 
fluid from children aged 0–7 years, both Gangell et al. and 
Sagel et al. [14, 15] found that positive S. aureus culture was 
linked to a higher degree of airway inflammation, as measured 
by increased neutrophil count and IL-8. In another study, lung 
damage (bronchiectasis) in early CF was recorded by CT scan 
and S. aureus was the most commonly isolated organism [16]. 
Conversely, in adult CF patients, S. aureus infections, in the 
absence of P. aeruginosa, are a marker of milder disease [1]. 
There is also an indication that methicillin- sensitive S. aureus 
may inhibit P. aeruginosa, thus delaying lung disease progres-
sion [17]. The evidence that early S. aureus infection worsens 
prognosis for CF patients remains conflicting and warrants 
further study [3, 18].
The lack of understanding regarding the role of S. aureus in 
the development of lung disease in CF has led to debate over 
the use of anti- staphylococcal prophylaxis early in life. Studies 
by Ratjen et al. and Stutman et al. [19, 20] linked the use of 
broad- spectrum antibiotics to an increase in P. aeruginosa 
isolation. However, a recent Cochrane review [21] showed 
no effect of anti- staphylococcal prophylaxis on P. aeruginosa 
colonization at 3–4 years. There was a suggested trend towards 
higher rates of P. aeruginosa at 4–6 years but as the studies 
reviewed did not last more than 6 years, conclusions about 
the long- term effects of prophylaxis could not be drawn. A 
pragmatic randomized controlled trial is currently in progress 
(http://www. cfstart. org. uk).
In addition to the lack of clarity over the clinical consequences 
of S. aureus colonization, there is also a gap in our mechanistic 
understanding of the microbiology of S. aureus in CF. The 
interaction of S. aureus with the pulmonary airway in CF, and 
its subsequent role in pathogenesis, is not clearly documented. 
CF epithelial cells have been shown to have an increased 
abundance of aGM1, a receptor that binds S. aureus and 
P. aeruginosa, compared with WT epithelia [22], and an 
in vitro study by Schwab et al. demonstrated that bacterial 
adherence to a bronchial epithelial cell line was significantly 
greater for CF S. aureus isolates than non- CF [23]. McKenney 
et al. also show aggregates of S. aureus are visible on the 
surfaces of bronchial sections from children with CF [24]. 
Yet, the only other study we found with direct evidence of 
S. aureus infection in human biopsy specimens, demonstrated 
that S. aureus did not adhere to the airway epithelium but was 
found aggregating within the mucus [25]. Furthermore, these 
authors cited several studies reporting an ability of S. aureus to 
bind mucins [26, 27]. It is obvious that better understanding 
of just how S. aureus colonizes the airway in CF is required, 
as there are unambiguous data on the underlying mechanisms 
of pathogenesis and virulence, and the influence of S. aureus 
on subsequent infection by other micro- organisms.
Mice are the most commonly used animal model of pulmo-
nary infection in CF. Mouse models have been used to 
identify virulence- related genes in pathogens and to test 
novel therapeutic agents aimed at reducing inflammation or 
infection [28]. However, mouse models present a number of 
challenges. In particular, mice do not develop spontaneous 
P. aeruginosa endobronchial infection, suppurative lung 
disease and mucus plugging of the airways, that are funda-
mental characteristics of human CF progression [29]. 
S. aureus does not appear to readily colonize the airways of 
mice or produce an inflammatory response, even when clinical 
strains are used, in the presence of mucus [30]. Furthermore, 
S. aureus forms severe abscess- like lesions in the mouse lung 
[31]. When lung abscess does occur in humans, S. aureus is 
the most commonly isolated organism [32]. However, lung 
abscess is rare in children [33] and even more so in people 
with CF: since the advent of neonatal screening and survival 
past infancy, abscesses are almost never observed in the CF 
population [34–36].
We previously developed a clinically relevant, high throughput 
model of chronic bacterial infection in CF. By combining 
sections of porcine bronchiole (obtained post- slaughter from 
a commercial abattoir) with a synthetic CF sputum medium 
(SCFM) [37] we have shown that we can study another key CF 
pathogen, P. aeruginosa, in a physicochemical environment 
similar to that present in vivo [38–40]. The use of CF- like 
growth medium combined with animal tissue with a greater 
structural, chemical and immunological similarity to human 
lung [41] means that our model is likely to facilitate a more 
human- like pathology of S. aureus than that observed in 
mouse models or in vitro studies. Using clinical reference 
strains and CF isolates of S. aureus, we can now demonstrate 
that in a CF- like environment, S. aureus shows non- invasive 
pathology. Bacteria grow as aggregates associated with the 
surface of bronchioles and in the surrounding artificial 
Impact Statement
Chronic bacterial infection is one of the main causes 
of declining lung function and morbidity in people with 
cystic fibrosis (CF). Staphylococcus aureus is the most 
prevalent organism isolated from the airways of infants 
with CF. Yet its overall role in the pathogenesis of pulmo-
nary disease is poorly understood. More accurate, high 
throughput models of CF lung infection are necessary to 
explore the interactions between S. aureus and host in 
this context. In vitro studies cannot accurately replicate 
chronic disease characteristics, such as the presence 
of small colony variants, and animal models also do not 
represent features of clinical disease. Mice, in particular, 
are not readily colonized by S. aureus and when an infec-
tion is established it leads to the formation of abscess, a 
phenomenon not observed in the human CF lung. Here 
we show an existing ex vivo pig lung model of CF infec-
tion supports the growth of S. aureus and that S. aureus 
demonstrates clinically significant characteristics, 
including appearance of small colony variants, increased 
antibiotic tolerance and preferential growth as aggre-
gates in mucus.
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sputum, without the formation of abscesses or other significant 
ultrastructural changes to tissue. In fact, we report a potential 
preference for aggregation in the surrounding mucus rather 
than growth associated with the bronchiolar surface. We also 
report the appearance of sub- populations of SCVs. Our work 
is consistent with S. aureus adopting a ‘persister’ rather than 
‘invader’ strategy in CF. This stands in marked contrast to the 
pathology of this species in mouse and cell- culture infection 
models, and underlines the importance of selecting models 
that reflect host–pathogen interactions more closely, in order 
to reliably study the role of specific bacteria in clinical disease 
progression. A better understanding of S. aureus pathology 
in the highly idiosyncratic environment of the CF lungs will 




USA300LAC Los Angeles County clone (JE2, BEI resources) 
was used as an example of a well- documented clinical strain. 
In total, 18 S. aureus strains isolated from nine people with 
CF at Hospital Universitari i Politecnic La Fe were included 
as exemplars of CF- associated strains. The strains used in this 
work were extracted for diagnostic purposes and sent to the 
microbiology service for routine analysis. Once analysed, and 
instead of being discarded as usual, the strains were grown 
in tryptic soy broth and kept in glycerin. We chose isolates 
that represented a range of patient clinical presentation and 
bacterial phenotypes (e.g. weak or strong biofilm formation 
as measured by in vitro attachment assays, and isolates from 
patients during periods of stable presentation and episodes of 
acute exacerbation) (Table S1, available in the online version 
of this article).
Media and culture conditions for growth in the ex 
vivo pig lung (EVPL) model
For use in the lung model, bacterial stocks were grown 
overnight at 37 °C on lysogeny broth (LB) agar. SCFM was 
prepared according to Palmer et al. [37] with the modification 
that we removed glucose and supplemented with 20 µg ml−1 
ampicillin. Our previous work suggested that glucose facili-
tated the growth of endogenous bacteria present in the lungs 
and that ampicillin helped to limit the growth of any resident 
bacteria in the lung that remained after sterilization [38]. We 
selected a concentration of ampicillin that provided the best 
possible coverage against endogenous populations but was 
sub- inhibitory for the S. aureus strains used (confirmed by 
standard MIC testing at the time of collection).
The EVPL model was adapted from our group’s previous 
work [38, 39], which in turn built on prior use of pig lungs 
for non- CF studies [42]. Briefly, lungs were collected from 
a local butcher (Steve Quigley and Sons, Cubbington, 
Warwickshire, UK) as soon as possible following abattoir 
delivery, and processed immediately upon arrival at the 
laboratory. Previous antibiotic administration history of the 
pigs is not known, but use of antibiotics as growth promoters 
is banned in the EU, so use is restricted to prophylaxis and 
mass medication of herds only when infection is suspected. 
Approximately 5 mm2 sections of bronchiolar tissue were 
dissected from the lung under sterile conditions. During 
dissection the sections were washed three times with a 1 : 1 
mix of RPMI 1640 and Dulbecco’s Modified Eagle Medium 
(DMEM) (Sigma- Aldrich), supplemented with 50 µg ml−1 
ampicillin, and then rinsed once in sterile SCFM without 
ampicillin supplementation. Bronchiolar samples were trans-
ferred to a clean petri dish and sterilized under a UV lamp 
for 5 min. Previous work has shown that tissue damage as a 
result of UV sterilization is minimal (not visible using light 
microscopy)
[39]. Samples were transferred to 24- well tissue culture plates: 
each well contained 400 µl SCFM supplemented with 0.8% 
w/v agarose to form a soft pad. Tissues were inoculated with 
the appropriate strain of bacteria using a sterile hypodermic 
needle (29G). The tip of the needle was lightly touched to 
the surface of the chosen S. aureus colony, and then used 
to pierce the surface of bronchiolar tissue for inoculation. 
A sterile needle was used for mock infection in uninfected 
controls. Then, 500 µl of SCFM+ 20 µg ml−1 ampicillin was 
added to each well and the plate was sealed with a Breath- 
Easier membrane (Diversified Biotech). Plates were incubated 
at 37 °C for up to 7 days and refreshed with 300 µl of SCFM+ 
20 µg ml−1 ampicillin at 48 h. Following incubation, tissue 
was rinsed in 1 ml PBS to remove loosely adhering cells and 
processed for colony counts and microscopy.
Bacterial load assay
Tissue samples used to assay total bacterial numbers in 
tissue- associated biofilm were homogenized individually 
in 1 ml PBS in reinforced metal bead tubes (Fisherbrand) 
using a FASTPREP 24 5G homogenizer (MP Biomedicals) 
for 40 s at 4.0 m s−1. Homogenates were serially diluted 
and aliquots were plated on LB and mannitol salt (MSA) 
agar (Oxoid, Thermo Scientific) to obtain single colonies. 
MSA agar is selective for Staphylococcus and was used to 
determine colony numbers of test strains and ensure that 
negative controls did not contain any S. aureus already 
resident in the lung tissue prior to experimentation. Non- 
selective LB agar was used to check for contamination or 
growth of endogenous populations. When the bacterial 
load in SCFM surrounding the lung tissue was measured, 
300 µl of SCFM was taken from each well at the same time 
as tissue processing and transferred to a sterile Eppendorf 
tube. Samples were vortexed, serially diluted and plated in 
the same way as tissue homogenate.
LB plates were incubated aerobically at 37 °C for 18–24 h and 
MSA plates were incubated in at 37 °C 5 % CO2 for 24 h and 
then for an additional 48 h at room temperature in ambient 
CO2 to allow visualization of slow- growing colonies. Total 
numbers of S. aureus recovered from the complete sample 
were calculated from tissue and SCFM colony numbers 
combined.
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Microscopy
Replica 5 mm2 bronchiolar tissue samples, dissected and 
inoculated as above, were preserved for haematoxylin and 
eosin staining. Samples were placed in individual tissue 
processing cassettes (Simport) and fixed overnight in 10 % 
neutral buffered formalin (NBF) at approximately 20 times 
w/v. Longitudinal, step sections (100 µm) were prepared 
for histopathology by an external service (University of 
Manchester). If samples required storage before transport, 
they were placed in 70 % ethanol and kept at 4 °C for up 
to 7 days. Sections were transported in PBS with residual 
NBF. In addition, 10 µl samples were taken from the SCFM 
surrounding lung tissue, diluted 1 : 10 in PBS and 5 µl drops 
prepared for Gram stain.
Microscopy was conducted with an Axio scope.A1 light 
microscope (Carl Zeiss) with AxioCam ERc5S digital camera 
and images processed in Zen Pro 2.1 Blue edition.
Colony identification
Colonies that were able to grow on MSA plates and ferment 
mannitol (indicated by yellow pigmentation of colony and 
surrounding clear zone) were regarded as S. aureus. Colony 
morphology was recorded by digital photography. The 
identity of colonies that were weak fermenters or small in 
size was initially confirmed using hydrogen peroxide to test 
for the production of catalase and then a staphylase assay 
(Oxoid). If SCVs were suspected, colonies were recovered by 
aerobic incubation overnight on Columbia Blood Agar and 
morphology was compared to the originally inoculated parent 
strain. PCR of large and small colonies from MSA plates was 
used to verify taxonomic identity. First, we performed colony 
PCR using Staphylococcus- specific primers [43]. Once genus 
was confirmed, amplification of the 16 S- 23S rRNA intergenic 
spacer region and Sanger sequencing was used to confirm 
that SCVs were S. aureus (primers 5′-TGCCAAGGCATC-
CACCG-3′ and 5′- GGCTGGATCACCTCCTT-3′).
Determination of antibiotic susceptibility by 
microdilution
The MIC of flucloxacillin against a pair of representative 
MSSA isolates (FQ128 and FQ142) and the standard MSSA 
control strain, ATCC29213, was determined according to the 
British Society of Antimicrobial Chemotherapy guidelines 
for microdilution [44] before examining antibiotic tolerance 
in the EVPL model. All isolates were from sputum samples 
collected from people with CF during stable presentation. All 
three strains demonstrated an MIC of <0.0625 mg l−1 and were 
sensitive to flucloxacillin, MIC breakpoint for resistance is 
0.12 mg l−1 (BSAC Guidelines).
Antibiotic tolerance in the EVPL model
Infected lung bronchioles incubated for 48 h as described 
above. At 48 h ‘pre- dose’ tissue samples were homogenized 
and assayed as above. Biological replicates (four bronchiolar 
sections for each strain and condition) were challenged with 
antibiotic: tissue samples were washed in PBS then placed in a 
new 24- well plate on agar pads. Thereafter, 500 µl SCFM alone 
was added for controls and 500 µl SCFM +either 0.25 mg l−1 
or 5 mg l−1 flucloxacillin for antibiotic tolerance test samples. 
Concentrations were calculated from the recorded broth MIC 
of <0.0625 mg l−1 for the strains tested and the clinical target 
pharmacokinetic (PK) parameters. The PK parameter for 
beta lactam efficacy is T >MIC with a target of 50 % of dosing 
interval at a free plasma concentration 4–5×MIC [45]. Then, 
5 mg l−1 was included to account for potential protein binding, 
which is 95 % for flucloxacillin [46]. Plates were incubated at 
37 °C. At 4 and 24 h post- dose, treated tissues were washed 
in PBS to prevent any antibiotic carryover, and all samples 
homogenized and plated as described above. The bacterial 
loads in non- antibiotic and antibiotic treated tissues were 
compared.
Statistical analysis
All data were analysed using RStudio (Mac OS X 10.6+version 
1.0.153) (RStudio, https://www. rstudio. com) using linear 
models followed by ANOVA and post- hoc Tukey HSD tests 
where appropriate, or using Kruskall–Wallis tests, as specified 
in the text.
RESULTS
Clinical strains of S. aureus are able to colonize 
EPVL
Data taken from preliminary experiments (Fig. 1) showed 
that bacterial load (c.f.u.) recovered at 48 h was similar for a 
large range of S. aureus CF clinical isolates, and comparable 
to Los Angeles County clone of USA300LAC, a methicillin- 
resistant (MRSA) clinical isolate known to form biofilm [47]. 
Table S1 shows details of CF isolates. Samples were taken 
from people presenting either with acute exacerbation or in 
a stable condition (defined as chronic isolates). Isolates were 
grouped randomly and tested on three separate occasions. 
In each case, lung samples were dissected from a single lung. 
Differences in growth were distinguishable between strains 
(ANOVA. F2,40=1.9, P=0.02) but post hoc analyses showed no 
significant difference between any CF isolate and USA300LAC 
(RStudio, script available on request). The median values for 
S. aureus load recovered at 48 h were 1.64×105, 3.64×105 and 
6.1×105 c.f.u. respectively for lungs 1–3. Growth on Staphy-
lococcal selective media (MSA) was only observed on one of 
the uninfected controls (Fig. 1a).
S. aureus growth in association with bronchiolar 
tissue depends on strain and lung but trends are 
consistent over time
To verify the reproducibility of S. aureus numbers recovered 
from bronchiolar tissue and the ability to observe differ-
ences between strains, triplicate samples of USA300LAC 
and two clinical strains were inoculated into three further 
lungs taken from different pigs (Fig. 2) and incubation was 
extended to 7 days. Clinical isolate FQ151 was compared with 
FQ184, these strains were chosen as an appropriate example 
pair as they were both isolated from patients with similar 
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demographics, both MRSAs that form biofilm, and had both 
demonstrated comparable rates of recovery at 48 h from the 
same lung (Fig. 1). However, FQ184 was isolated during an 
acute disease exacerbation and FQ151 during stable presen-
tation (representing chronic infection or colonization) (Table 
S1). It was therefore hypothesized, that by comparing these 
two strains, differences between exacerbation- associated 
strains and those apparently persisting asymptomatically 
may be observed, and, if so, could be further investigated 
with a larger selection of paired isolates. Fig. 2 shows that 
USA300LAC was again able to establish in the lung and 
mean S. aureus load recovered at 48 h was 6.8×106 c.f.u. 
Mean yields for clinical strains at 48 h were 3.8×106 and 
5.5×105 c.f.u. for FQ184 and FQ151, respectively. By 7 days 
no colonies were recovered from tissue taken from one 
of the three lungs for either clinical strain, and counts for 
clinical strains in a second lung were below or close to the 
lower limit of detection. Average c.f.u. counts at day 7 were 
4.2×103 for USA300LAC, 7.9×103 for FQ184 and 8.1×103 
for FQ151. The data were analysed by ANOVA to test for 
differences between strains, lungs and days, and interactions 
between day*lung and strain*lung. Total bacterial load was 
significantly different once again between strains (F2,40=12.0, 
P <0.001) and between lungs (F2,40=6.03, P=0.005). There was 
a main effect of day (F1,40=155, P <0.001) and the magnitude 
of the drop between 48 h and 7 days did not vary significantly 
between lungs (day*lung interaction F2,40=9.5, P=0.110) or 
between strains (strain*day interaction F2,40=1.73, P=0.190). 
Different lungs did, however, affect the growth of the strains 
differently (lung*strain interaction F4,40=2.62, P=0.049).
S. aureus is visible as aggregates at the airway–
tissue interface but does not appear to invade 
tissue
Monitoring bacterial load within the model by c.f.u. count 
shows that the model can maintain a S. aureus popula-
tion at 48 h. In addition, it was important to investigate 
whether the consistent decline in c.f.u. counts by 7 days 
was due to the inability of the model to support S. aureus or 
whether adaptation of S. aureus within the model prevented 
sufficient monitoring, for example if cells were growing in 
strongly adherent biofilm that had not been washed off, 
or as SCV or persister cells that were difficult to recover 
on media. Therefore, samples were histologically examined 
to gain a better understanding of growth characteristics in 
the model. Replicate samples of the inoculated lung tissue 
(5 mm2, dissected from bronchi, as for original model) 
were washed in PBS and prepared for microscopy, by 
longitudinal, step section (100 µm), at 2 and 7 days post- 
infection. Histopathological staining (Figs 3 and 4) showed 
bronchial mucosa, represented by mature cartilage. In 
infected samples there is clear evidence of polymorphonu-
clear leukocytes and organisms, including, predominantly 
Gram- positive bacilli. Polymorphonuclear leukocytes and 
organisms are largely absent from uninfected controls with 
the exception of a small number of rod- shape organisms 
(Fig. 3b). Gram- positive bacilli aggregate primarily at the 
tissue–airway interface of infected lungs and their absence 
from the uninfected lung, (Figs 3a, b and 4a, b) strongly 
suggests that they are the S. aureus deliberately inoculated 
into test samples. Lung tissue remained largely intact across 
all tested isolates, even at 7 days. There was some disruption 
Fig. 1. Recovery of S. aureus following 48 h in the EVPL. Each S. aureus isolate was inoculated into four replica bronchiolar sections of 
tissue (a single pair of lungs was used on each of 3 separate days). Uninfected tissue was used as a control. Samples were destructively 
sampled at 48 h post- infection. S. aureus bacterial load was recovered on selective media (MSA) and is measured as total c.f.u. per 
lung sample (total c.f.u.). Solid lines indicate median values and the limit of detection is shown as a dashed line, no colonies were 
observed on plates where data is at the limit of detection. USA300LAC is used as a representative control strain, known to form biofilm. 
Clinical isolates were supplied by the Instituto de Investigación Sanitaria La Fe (Table S1) and numbers are designated as supplied. 
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of tissue integrity at the surface, illustrated by the pres-
ence of fibrinous material (highlighted with *). None of 
the samples show any evidence of abscess, which would 
present as a clearly defined, bordered structure. S. aureus 
is present only at the tissue–airway interface and does not 
appear to demonstrate tight association with tissue in the 
form of a mature biofilm, although more specific staining 
for biofilm would be required to confirm this. Replica 
images confirmed histological presentation (Figs S1–S4).
Evidence of other organisms in some samples, for example 
rod- shaped cells in the tissue infected with FQ184 at 48 h 
(arrow, Fig. 3f, ×100 magnification), is likely to be endog-
enous populations present prior to dissection (healthy 
lungs are not sterile) or contaminants not removed during 
sterilization; they are also present in the uninfected 
control (arrow, Fig. 3b). Interestingly, when other bacteria 
are present, there appear to be distinct ecological niches 
within the lung environment with Gram- positive bacilli 
clustered primarily at or near the surface, and rods present 
embedded within smooth muscle and connective tissue. 
This supports much of the current understanding of the 
structural architecture of polymicrobial communities and 
it would be useful to study this further especially as the 
presence of other bacteria may affect the ability of S. aureus 
to survive and adapt within the model. By day 7, cells in 
clusters of FQ151 were small and poorly stained, and thus 
difficult to image (Fig. 4d). This may indicate the cells are 
no longer viable and explain the lack of colonies recovered 
on plates (Fig. 2). Although inconclusive, the images appear 
to suggest that there is still a presence of bacterial cocci in 
association with the lung tissue at 7 days post- inoculation, 
despite poor recovery of colonies on selective media. It 
highlights that sputum sampling and colony count alone 
cannot reliably determine the presence of S. aureus popu-
lations that may be viable but non- culturable. It would 
be useful to further investigate, perhaps with the use of 
Staphylococcus aureus specific fluorescent probes or live 
dead staining in order to confirm the identity and viability 
of the cells.
Fig. 2. Recovery of an exacerbation vs chronic CF isolate of S. aureus in the EVPL. S. aureus isolates were inoculated into six replica 
bronchiolar sections of tissue from each of three independent pairs of lungs, and samples were destructively sampled at 48 h and 7 days 
post- infection by removing the tissue section from surrounding SCFM and bead beating to release adherent bacteria. S. aureus bacterial 
load was recovered on selective media (MSA) and measured as total c.f.u. per tissue sample (c.f.u.). Triplicate lungs are indicated by point 
shape, and lines represent mean values. The limit of detection is shown as a dashed line. Colony counts on MSA, for uninfected tissue, 
were not recorded above the detectable limit at 48 h demonstrating that there was no inherent S. aureus presence in the lung tissue 
prior to inoculation. USA300LAC is used as a representative control strain. CF isolates supplied by the Instituto de Investigación Sanitaria 
La Fe and numbers are designated as supplied. ANOVA conducted on log- transformed data revealed significant main effects of strain 
(
i2,40
=12.0, P <0.001), lung (F
2,40
=6.03, P=0.005) and day, and a significant interaction between lung and strain (F
4,40
=2.62, P=0.049). There 
was no significant interaction between day and lung (F
2,40
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S. aureus aggregates in artificial sputum 
surrounding lung tissue
Initial experiments (Figs 1 and 2) only recorded bacterial 
burden recovered from washed tissue pieces. The histology 
suggests at least some S. aureus may be tightly associated 
with the tissue in the model and not removed during homog-
enization. In addition, there is evidence in the literature to 
suggest S. aureus may preferentially bind to mucus plugs in 
the airways of the CF lung, rather than associating with the 
tissue surface [25]. Both are possible explanations as to why, 
Fig. 3. H and E stain of representative lungs at day 2. Uninfected control (a, b) and 48 h post- inoculation with FQ151 (c, d) FQ184 (e, f) or 
USA300LAC (g, h). ×20 magnification (a, c, e and g). Highlighted area of interest (rectangle) is shown at ×100 magnification (b, d, f and 
h). Scale bars represent 50 µm and 10 µm accordingly. Cocci- shaped cells are present in all inoculated tissue at ×100 (d, f and h) but not 
uninfected control (b) Disruption to bronchiole tissue is also evident in all infected samples (*) less extensive for FQ184 (e) a strain taken 
during acute exacerbation, but more marked for USA300LAC (g) and not seen in uninoculated control (a) Arrows indicate the presence 
of rod- shaped bacterial cells in both uninfected (b) and inoculated (f) samples, suggesting the presence of endogenous lung species.
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despite presumably being adapted to the lung environment, 
c.f.u. loads associated specifically with the bronchiolar tissue 
showed such a marked drop by day 7.
A subset of clinical strains, two MRSA and two MSSA 
(methicillin- sensitive) strains, were chosen to investigate 
growth in the surrounding SCFM, and compared with 
USA300LAC (Fig. 5). When bacteria were also recovered 
from the surrounding SCFM and enumerated, the total c.f.u. 
count from the sample (tissue plus surrounding SCFM) was 
higher than the c.f.u. count for tissue only (Fig. 5a). Although 
Fig. 4. H and E stain of representative lungs at day 7. Uninfected control (a,b) and 7 days post- inoculation with FQ151 (c, d) FQ184 (e, f) 
and USA300LAC (g,h). ×20 magnification (a,c,e and g). Highlighted area of interest (rectangle) is then shown at ×100 magnification (b, 
d, f and h). Scale bars represent 50 µm and 10 µm accordingly. Clusters of cocci- shaped cells are present at or near the tissue–airway 
interface for all inoculated tissue at ×100 (d, f and h) but not uninfected control (b).
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Fig. 5. Location of S. aureus in the EVPL model 48 h and 7 days: c.f.u. and proportion of c.f.u. recovered from artificial sputum media 
(SCFM) vs tissue. S. aureus isolates were inoculated into six replica bronchiolar sections of tissue from each of three independent pairs 
of lungs, and samples were destructively sampled at 48 h and 7 days post- infection. Aliquots of the SCFM surrounding each sampled 
piece of tissue were also assessed for bacterial load. USA300LAC was used as representative control strain and an uninfected lung 
used as a negative control. Clinical isolates supplied by the Instituto de Investigación Sanitaria La Fe and numbers are designated as 
supplied. (a) S. aureus cell counts recovered on MSA agar from EPVL at 48 h and 7 days. Bacterial load measured as total c.f.u. per tissue, 
surrounding SCFM or total sample (c.f.u.). Counts were taken from triplicate lungs, indicated by point shape. Non- parametric Kruskal–
Wallis tests were used to test for differences in the proportion of bacteria in the surrounding SCFM at 48 h and 7 days. Increases in 
proportional growth in SCFM were found for strains FQ128 (Chi- squared=7.44, P=0.006, df=1), FQ140 (Chi- squared=11, P <0.001, df=1), 
FQ151 (Chi- squared=7.1, P=0.008, df=1) and USA300LAC (Chi- squared=12.3, P <0.001, df=1). FQ142 showed no significant increase 
in SCFM proportion (Chi- squared=1.2, P=0.22, df=1). (b) Proportion of total c.f.u. recovered from tissue vs surrounding SCFM at 48 h 
and 7 days. Line shows equal c.f.u. in SCFM and tissue, for reference. Minimum limit of detection 4.3×101. Linear models on log- log 
transformed data showed a significant correlation between growth associated with tissue and growth in surrounding SCFM at both time 
points. (Full details of ANOVA results are given in the Supplementary Material, R2adj for models testing for effects of lung, strain, c.f.u. 
lung and strain*c.f.u. lung on c.f.u. in SCFM were 0.50 for 48 h data and 0.36 for day 7 data.
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‘mucus plugs’ do not form in the model, aggregates of S. aureus 
cells were visible in Gram stains of surrounding SCFM at day 
seven for all strains tested (Fig. S5) and by day 7, a greater 
proportion of the total bacterial population was consistently 
found in the surrounding SCFM than in tissue- associated 
biofilm (Fig. 5b). The four biofilm forming strains all showed 
a significant increase in the proportion of recoverable cells 
in the SCFM between 48 h and day 7 as measured by the 
Kruskal–Wallis test (FQ128 χ2=7.44, FQ140 χ2=11, FQ151 
χ2=7.1, USA300LAC χ2=12.3; all P- values ≤0.008). FQ142 did 
not show a significant increase in SCFM proportion between 
the two time points (Kruskal–Wallis test, χ2=1.2, P=0.22). 
FQ142 is not a biofilm former (Table S1), and so likely to have 
a higher proportion already in the SCFM by 48 h. SCFM is a 
minimal media and it is significant that there are viable cells 
are maintained in the SCFM for 7 days with limited nutrient 
replenishment, suggesting the addition of lung tissue to the 
model is an important improvement.
Tissueassociated populations demonstrate 
phenotypes consistent with chronic infection
The data collected by cell enumeration (Figs 1, 2 and 5), for 
growth and localization of S. aureus in the model, suggest 
the existence of subpopulations present during chronic infec-
tion. These likely comprise aggregates of cells in the mucus 
and a smaller percentage of tissue or biofilm- associated cells, 
which may be slow- growing SCVs or non- growing persisters. 
If this is the case it would be consistent with hypotheses in 
the literature regarding S. aureus infection [48], and we would 
anticipate that there would be SCVs present in the model and 
the ‘persister’ subpopulation would demonstrate increased 
antibiotic tolerance.
Small colonies (<50 % diameter of usual S. aureus colonies) 
were observed on MSA plates after incubation for at least 48 h 
in 5 % CO2 at 37 °C for samples taken 7 days post- inoculation. 
Example colonies were photographed (Fig. S6) and some had 
weak catalase and coagulase results when tested, weak catalase 
is indicative of deficient haem production and is associated 
with SCVs, as is weak coagulase. SCVs were confirmed as 
S. aureus spp. using genus- specific primers (STaG) [43] 
followed by sequencing of the 16 s- 23S intergenic region 
(Table S2).
Antibiotic tolerance of tissue-associated 
aggregates
Slow- growing or biofilm bacterial populations may be 
tolerant to antibiotics and implicated in the persistence of 
chronic infection. Tolerance of tissue- associated aggregates 
to flucloxacillin was assessed for a pair of clinically isolated 
MSSAs that were susceptible to flucloxacillin in a standard 
MIC microdilution and had the same MIC as the control 
strain ATCC29213 (<0.0625 mg l−1). They were isolated 
from people who presented asymptomatically (without 
exacerbation) (Table S1). Lung tissue was infected with 
S. aureus and incubated as described above. At 48 h, anti-
biotic test samples were challenged with a single dose of 
either 0.25 mg l−1 or 5 mg l−1 (to account for potential protein 
binding) flucloxacillin; growth control samples were main-
tained in SCFM alone and uninfected lungs used as a nega-
tive control. Tissue was processed at 4 and 24 h post- dose 
and total S. aureus load recorded as before (Fig. 6a). As in 
previous experiments, uninfected control tissues showed 
no growth on MSA plates. Clinically, bactericidal activity of 
an antibiotic is regarded as a reduction of 99.9 % (>3 log10 
decrease) in the c.f.u. ml-1 of the original sample. The data 
presented in Fig. 6b demonstrates that a mean decrease of 
>3 log10 was only achieved against FQ142 when challenged 
with the higher concentration of 5 mg l−1 flucloxacillin for 
24 h, despite all three strains demonstrating susceptibility in 
a standard MIC test. For ATCC29213 there was no significant 
effect of dose (ANOVA, f2,21=0.2 P=0.8) or dosing interval 
(ANOVA, f2,21=1.9 P=0.2) on c.f.u. ml
-1. Although there was 
an overall significant effect of dose on c.f.u. ml-1 for FQ128 
(ANOVA, f2,21=5.8, P=0.01) and FQ142 (ANOVA, f2,21=7.5, 
P=0.004), post hoc analysis showed this was not significant 
for 0.25 mg l−1 (FQ128, P=0.8 and FQ142, P=0.2) and a mean 
decrease in c.f.u. ml-1 of >3 log10 was not achieved for either 
strain at this concentration (Fig. 6b). Dosing interval was 
found to be significant for FQ128 (f 2,21=7.2, P=0.004) but 
not for FQ142 (f 2,21=0.03, P=0.97). The fact that the required 
bactericidal target was not reached for the control strain, 
ATCC29213, and that the response of the two clinical isolates 
varied, shows that standard MIC testing may not reliably 
predict clinical response to antibiotic regimes. There was no 
significant decrease in bacterial recovery between pre- dose 
and 24 h post- dose when challenged with 0.25 mg l−1 flucloxa-
cillin and FQ142 showed a potential to grow under these 
conditions, suggesting sub- inhibitory flucloxacillin concen-
trations could lead to selection for resistance. Furthermore, 
although 5 mg l−1 flucloxacillin had a significant effect on c.f.u. 
ml-1 for both clinical strains, it failed to cause a mean decrease 
in FQ128 c.f.u. ml-1 of >3 log10, suggesting that some strains 
could tolerate clinically relevant concentrations even when 
antibiotic protein binding is accounted for. This was a very 
small sample set, and further investigation is warranted, but, 
it indicates that maintaining plasma concentrations above the 
target of 4×MIC may be necessary for effective treatment of 
S. aureus infection in CF.
DISCUSSION
Growth and localization of S. aureus in EPVL
There is an apparent contradiction between the usual 
pathology of S. aureus in human CF samples (non- invasive) 
and in standard laboratory models using cell- culture or mouse 
lung infections. To address this gap between the clinical 
norm and standard lab models, we grew a biobank of clinical 
isolates in an ex vivo model of CF lung infection, which care-
fully mimics human tissue structure and the chemistry of CF 
lung secretions. S. aureus grew with reasonable consistency, 
both associated with lung tissue, at the airway surface, and 
as bacterial aggregates in artificial sputum (SCFM) around 
the tissue. S. aureus bioburden was maintained in EPVL over 
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7 days, although tissue- associated c.f.u. numbers were dimin-
ished over this period and in general the bacteria showed a 
preference for growth as aggregates suspended in the SCFM.
Defined biofilm was not investigated in histological samples, 
although there was evidence of potential biofilm architec-
ture and increased structure in bacterial populations for 
some samples by 7 days compared to 48 h. Interestingly, we 
have recently reported that P. aeruginosa does demonstrate 
extensive biofilm growth in the EPVL that can be observed 
using the same histological staining techniques [40]. This is 
consistent with the available clinical evidence where exten-
sive biofilms have not been described for S. aureus in the CF 
lung [49], but small, biofilm- like aggregates are reported in 
the sputum and on the surface of airways [24, 25, 50, 51]. 
Consistent with growth as aggregates in vivo, there is evidence 
that S. aureus switches off the global regulator agr in CF [48].
We did not observe interstitial invasion by S. aureus. Gener-
ally, interstitial bacteria are rarely observed in biopsy samples 
from people with CF (even if significant interstitial inflamma-
tion is observed) and bacteria in the airways are confined in 
luminal mucus plugs or occasionally attached to defined foci 
of epithelial erosion; this lack of tissue invasion is consistent 
with the rarity of bacteremia in people with CF [24, 25, 52–57]. 
CF lung disease thus presents as bronchiectasis with mucous 
plugging of small airways. In contrast, microscopy images 
presented in studies of murine pulmonary S. aureus infections 
typically show abscesses (a cavitating, pus- filled lesion within 
the tissue with a defined border: see Fig. 2 in [31] and Fig. 2 
in [58], for examples) and lead to chronic pneumonia [59]. 
Clearly, there are significant differences in S. aureus pathology 
in mouse models versus the highly specialized environment 
of CF airways as approximated by the ex vivo pig lung model.
In light of this, it is significant that our results suggest prefer-
ential localization of S. aureus in the SCFM surrounding the 
tissue sections, as opposed to epithelial surface attachment, 
and we did not observe the appearance of abscess- like struc-
tures. S. aureus can cause lung abscess in humans – in fact it 
is one of the most common bacteria isolated from abscesses 
[60] – but abscesses are almost never observed in people with 
CF [56, 57]. A specific Panton- Valentine Leukocidin positive 
strain of MRSA was associated with invasive, cavitating lung 
lesions in a CF centre in the USA in the mid 2000s [61], but 
this is unusual. Other than this specific outbreak, a literature 
search revealed only five cases of abscess among people with 
CF, only two of which were associated with S. aureus: one 
patient was co- colonized by P. aeruginosa and the other with 
P. denitrificans [34, 62]. It should be noted that abscess forma-
tion is associated with the presence of neutrophils, our model 
uses post- mortem tissue and, therefore, the effect of the 
host immune response is not observable. In addition, tissue 
samples in our model are taken only from the bronchi wall 
and so may not capture abscess formation. However, given 
the rarity of clinical evidence for invasive S. aureus infection 
in people with CF, induction of abscess formation may not 
Fig. 6. Recovery of S. aureus clinical isolates from EPVL following flucloxacillin challenge. Each S. aureus isolate was inoculated into 
replica bronchiolar sections of tissue from the same pair of lungs, and incubated as previously described for 48 h. Four replica samples 
were processed for counting of bacterial load, prior to antibiotic challenge (0 h, pre- dose). Remaining samples were moved to SCFM 
containing either no antibiotic (circles), 0.25 mg l−1 (triangles) or 5 mg l−1 (diamonds) flucloxacillin and incubated for 4 or 24 h. Uninfected 
tissue pieces were used as control and processed as infected replica, no colonies were observed on recovery plates for uninfected 
controls and so c.f.u. was recorded as at the limit of detection (stars). Lines represent mean bacterial load. All isolates were classified 
as sensitive by standard antibiotic susceptibility testing (MIC<0.0625 mg l−1). Bactericidal activity, (>3 log
10
 in c.f.u.) was only observed 
against FQ142 when challenged with 5 mg l−1 flucloxacillin for 24 h (Fig. 6b, highlighted). Antibiotic dose had no significant effect for 
ATCC29213 (ANOVA, f
2,21
=0.2 P=0.8) for clinical strains there was an overall effect of dose: ANOVA, f
2,21
=5.8, P=0.01 and f
2,21
=7.5, P=0.004 
for FQ128 and FQ142, respectively. However, post hoc analysis revealed there was no significance for either strain when exposed to 
0.25 mg l−1 flucloxacillin (FQ128, P=0.8 and FQ142, P=0.2).
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be clinically important in a CF model. Clinical observations 
are consistent with a study in which mucus hypersecretion 
was induced in cultured primary nasal epithelia cells to better 
mimic conditions in the CF lung: mucus presence led to 
S. aureus cells moving away from the epithelial cell surface 
and growing in the mucus [25] – as observed in our model.
Chronic infection phenotypes of S. aureus in EPVL
The tissue- associated subpopulation exhibited enhanced 
tolerance to flucloxacillin compared with standard suscep-
tibility assay results. This is likely due to physiological cues 
from the lung environment and the appearance of a subpopu-
lation of SCVs [11, 13, 63–65] but may also be influenced by 
the presence of biofilm structure matrix if it is present (which 
could usefully be explored in future work).
Small colony variants emerged once S. aureus isolates were 
passaged through the EPVL. The phenotypic development 
of SCVs has been linked to chronic CF infections [63, 64]. 
The impact of SCVs on virulence and persistence is difficult 
to study in vitro, as they rapidly revert to normal colony 
morphology when attempts are made to culture them [51], 
and it usually requires the creation of artificially generated, 
stable SCVs which may not fully represent those generated by 
the in vivo environment [66]. Notwithstanding these limita-
tions, studies have linked the SCV phenotype with attenu-
ated virulence [67] and a dampened host cytokine response 
[68, 69] – both changes that are consistent with the adoption 
of persistence strategy. The ability of the ex vivo lung model to 
cue SCV emergence is likely to be a significant strength of the 
model, permitting a rapid means to generate this phenotype 
and allowing more extensive future research into the effects 
of SCVs. It will be important, however, to tease apart the rela-
tive contributions of the presence of tissue and the presence 
of sub- inhibitory levels of ampicillin on SCV emergence. 
Since completing this work, we have begun a more extensive 
investigation of methods to reduce the presence of endog-
enous bacteria from the lung tissue, and we have found that 
expedited access to lungs after slaughter allows us to obtain 
tissue which requires less rigorous control measures. Future 
experiments using EVPL with different or no antibiotic 
supplementation will allow us to explore the impacts of tissue 
and antibiotic presence on microbial physiology.
Population heterogenicity of S. aureus in vivo and in 
EVPL
The evidence outlined above is consistent with S. aureus 
growing as phenotypically heterogeneous populations in CF 
– comprising tissue- associated, biofilm- like aggregates and 
mucus- embedded aggregates, with the potential presence of 
SCVs. Persistence, antibiotic tolerance, gene expression and 
ability to be cultured in vitro are likely to differ between these 
subpopulations, and understanding the differences within 
heterogenous populations could improve understanding of 
virulence mechanisms. If this is the case, the ex vivo pig lung 
model will be valuable in future studies, for the generation 
of heterogenous populations that are hard to reproduce in 
animal and traditional in vitro models.
Strengths and limitations of the EVPL model
Our data reinforce the notion that host- specific pathology is 
an important area of future study, with particular significance 
for S. aureus. Modelling S. aureus infection, in any tissue other 
than human biopsy, is likely to present differences and chal-
lenges. It is abundantly clear that both mouse and in vitro 
models fail to capture key features of pathology observed from 
human clinical data that are revealed by our EVPL model. 
Consequently, EVPL could fill an important gap in the toolkit 
for answering crucial questions about the microbiology and 
clinical impact of S. aureus in CF.
There are, of course, some areas where the model could be 
optimized for future use. Primarily, variability in S. aureus 
bacterial load was considerable. We inoculated tissue 
sections from single colonies, and not a standardized broth 
culture, as preliminary work with P. aeruginosa in an earlier 
version of the model showed no significant variation in the 
number of cells inoculated from single colonies, or the cell 
numbers recorded at 48 h [39]. Additionally, in CF there is 
unlikely to be a large burden of colonizing bacteria [70]. 
Given the differences in the way that P. aeruginosa and 
S. aureus grow in the model, starting inoculum may be a 
more significant determinant of the growth and survival of 
S. aureus and standardizing cell numbers could be important 
for future developments, for example assessing the impact 
of antimicrobial agents on viable bacterial burden. More 
broadly, better data on the variability in S. aureus aggregate 
size between foci of infection within CF lungs, and between 
patients, would be useful for understanding S. aureus 
pathology. In a study by Hirschhausen et al. [59], adaptive 
changes differed in patients infected with the same S. aureus 
clonal lineage, indicating that individual host factors had 
an impact on adaption. This is reminiscent of our results, 
which show significant variability between lungs taken from 
different pigs (Fig. 2).
We also stress, given the reported intraspecific phenotypic 
and genetic diversity of bacteria within and between people 
with CF, and given observed differences in the growth and 
localization of a pair of isolates taken from stable infection 
and acute exacerbation (Figs 2–4), future work could usefully 
explore a larger collection of isolates in more depth.
CONCLUSION
The ex vivo lung model is designed to maximize physico-
chemical similarity to chronically infected human CF airways. 
It is also high throughput and inexpensive, and because it uses 
post- consumer waste from the meat industry, it presents no 
ethical concerns [38]. Our results from S. aureus infection 
of the ex vivo model reveal aspects of chronic CF pathology, 
which are not captured by existing ‘gold standard’ animal 
models: aggregation of bacterial cells associated with tissue 
but also (perhaps predominantly) in mucus; the development 
of SCVs; and an increase in antibiotic tolerance. The potential 
preferential binding of S. aureus to mucus, and lack of tissue 
invasion, is a phenomenon that may have clinical relevance, 
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especially given current questions about the role of S. aureus 
as a CF pathogen and the consequences of trying to remove it.
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